A Novo Nordisk weight loss drug lowers BMI in kids as young as 6 - NBC News
A late-stage clinical trial showed liraglutide, similar to Ozempic, reduced BMI in kids ages 6-11 with obesity, with concerns about long-term safety and impact on growth. The trial included 82 children, with liraglutide resulting in a 5.8% average BMI reduction compared to a 1.6% increase in the placebo group. Novo Nordisk has applied to the FDA for approval of liraglutide for weight loss in this age group.
Related Clinical Trials
Reference News
Novo Nordisk's Saxenda showed a 5.8% mean BMI reduction in children aged 6-12 with obesity in a Phase III trial, compared to 1.6% in the placebo group. The trial data supports expanding Saxenda's label to include younger obese children, following its FDA approval for adolescents aged 12 and older.
Children receiving daily Saxenda injections reduced BMI by 5.8% on average in a 56-week trial, outperforming the placebo group by 7.4%. Novo Nordisk plans to seek FDA approval for Saxenda use in younger children, addressing the lack of obesity treatments for kids. The obesity drug market is expanding rapidly, with potential growth to $100 billion by 2030.
Novo Nordisk's study shows liraglutide, a weight-loss drug, is effective and safe for children aged 6-12, with a 7.4% BMI reduction over a year. The company plans to seek FDA and EMA approval, aiming to be the first to offer obesity treatment for this age group. Side effects include nausea and quick weight regain post-treatment, but no growth or puberty issues were noted.
Liraglutide (Saxenda) is safe and effective for children aged 6-12 in reducing BMI, per SCALE Kids trial results presented at EASD. Published in NEJM, the study shows a 7.4% BMI reduction compared to placebo, with improvements in blood pressure and blood sugar control. Liraglutide, a GLP-1 receptor agonist, is the first to be studied for pediatric obesity treatment.
Novo Nordisk's Saxenda (liraglutide) showed a 5.8% mean BMI reduction in children aged 6-12 with obesity in a Phase III trial, compared to 1.6% in the placebo group. The trial data supports Novo Nordisk's plan to expand Saxenda's label to include younger obese children.
A study shows liraglutide, combined with diet and exercise, is safe and effective for kids aged 6-11, reducing BMI and improving health markers. Novo Nordisk seeks US approval for this age group, aiming to treat common childhood obesity. Side effects, mainly gastrointestinal, were common but mostly mild. Experts emphasize careful consideration of risks and long-term effects.
A clinical trial shows Novo Nordisk's Saxenda (liraglutide) reduces BMI in children aged 6-11, with a 5.8% average reduction over 56 weeks, compared to a 1.6% increase in placebo group. Concerns remain over long-term safety and effectiveness, but obesity in this age group is a growing issue in the US.
Liraglutide (Saxenda) helped obese children aged 6-11 lower BMI and reach healthier weight, per a study in the New England Journal of Medicine. The drug, safe but with side effects like nausea, showed a 5.8% BMI drop in the liraglutide group vs. a 1.6% increase in the placebo group, though BMI rose again post-medication cessation. Experts suggest its potential for long-term health benefits despite current costs and need for further long-term studies.
Novo Nordisk tested its weight loss drug Saxenda on kids aged 6-12, finding it helped them reach a healthier weight. Saxenda, originally for type 2 diabetes, uses liraglutide and is an injection with side effects like nausea and diarrhea. Stopping its use may cause weight regain, but experts see it as a step towards treating childhood obesity.
Novo Nordisk's Saxenda showed a 5.8% mean BMI reduction in children aged 6-12 with obesity in a Phase III trial, compared to 1.6% in the placebo group. The company plans to use this data to expand Saxenda's label to include younger obese children.
A late-stage clinical trial showed liraglutide, similar to Ozempic, reduced BMI in kids ages 6-11 with obesity, with concerns about long-term safety and impact on growth. The trial included 82 children, with liraglutide resulting in a 5.8% average BMI reduction compared to a 1.6% increase in the placebo group. Novo Nordisk has applied to the FDA for approval of liraglutide for weight loss in this age group.